Knight Therapeutics Announces Health Canada Approval for NERLYNX^® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer

Knight Therapeutics, Inc. announced that Health Canada has approved NERLYNX® in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. The approval was based on results of the global Phase III NALA trial.